Loading…
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $377M | $-111M | $-78M | $-76M | -16.4% | 20.3% | - |
| 2024 | $313M | $-144M | $-209M | $-69M | -44.2% | 27.7% | - |
| 2023 | $245M | $-178M | $-205M | $-170M | -32.8% | 20.4% | - |
| 2022 | $204M | $-212M | $-218M | $-226M | -27.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 203.56 | 245.11 | 312.97 | 376.57 |
| Cost Of Revenue | 119.33 | 155.38 | 179.62 | 185.57 |
| Gross Profit | 84.23 | 89.73 | 133.35 | 191 |
| Operating Expense | 333.26 | 296.63 | 309.25 | 327.26 |
| Operating Income | -249.02 | -206.90 | -175.90 | -136.26 |
| EBITDA | -211.68 | -177.59 | -144.47 | -111.41 |
| EBIT | -228.19 | -206.90 | -175.90 | -136.26 |
| Pretax Income | -228.27 | -203.47 | -208.17 | -76.95 |
| Tax Provision | -10.41 | 1.15 | 0.56 | 0.72 |
| Net Income | -217.86 | -204.62 | -208.73 | -77.67 |
| Net Income Common Stockholders | -217.86 | -204.62 | -208.73 | -77.67 |
| Total Expenses | 452.59 | 452.01 | 488.88 | 512.83 |
| Interest Expense | 0.08 | 0.01 | 0.03 | 0 |
| Interest Income | 3.06 | 14.37 | 15.34 | 11.36 |
| Research And Development | 120.31 | 106.89 | 90.85 | 80.28 |
| Selling General And Administration | 212.95 | 189.74 | 218.40 | 246.98 |
| Normalized EBITDA | -230.53 | -167.34 | -99.54 | -160.25 |
| Normalized Income | -235.77 | -196.52 | -163.80 | -116.26 |
| Basic EPS | -4.04 | -3.60 | -3.60 | -1.30 |
| Diluted EPS | -4.04 | -3.60 | -3.60 | -1.30 |
| Tax Effect Of Unusual Items | 0.94 | -2.15 | 0 | 10.26 |
| Tax Rate For Calcs | 0.05 | 0.21 | 0 | 0.21 |
| Total Unusual Items | 18.85 | -10.26 | -44.93 | 48.85 |
| Total Unusual Items Excluding Goodwill | 18.85 | -10.26 | -44.93 | 48.85 |
| Net Income From Continuing Operation Net Minority Interest | -217.86 | -204.62 | -208.73 | -77.67 |
| Reconciled Depreciation | 16.51 | 29.31 | 31.43 | 24.85 |
| Reconciled Cost Of Revenue | 119.33 | 155.38 | 179.62 | 185.57 |
| Net Interest Income | 2.98 | 14.37 | 15.34 | 11.36 |
| Net Income From Continuing And Discontinued Operation | -217.86 | -204.62 | -208.73 | -77.67 |
| Total Operating Income As Reported | -234.78 | -217.16 | -220.83 | -136.26 |
| Diluted Average Shares | 53.88 | 56.88 | 58.02 | 59.81 |
| Basic Average Shares | 53.88 | 56.88 | 58.02 | 59.81 |
| Diluted NI Availto Com Stockholders | -217.86 | -204.62 | -208.73 | -77.67 |
| Net Income Including Noncontrolling Interests | -217.86 | -204.62 | -208.73 | -77.67 |
| Net Income Continuous Operations | -217.86 | -204.62 | -208.73 | -77.67 |
| Other Income Expense | 17.77 | -10.93 | -47.61 | 47.94 |
| Other Non Operating Income Expenses | -1.09 | -0.67 | -2.68 | -0.90 |
| Special Income Charges | 18.85 | -10.26 | -44.93 | 48.85 |
| Gain On Sale Of Business | 4.61 | 0 | 0 | 48.85 |
| Impairment Of Capital Assets | 0 | 6.79 | 44.93 | 0 |
| Restructuring And Mergern Acquisition | -14.24 | 3.47 | 0 | 0 |
| Net Non Operating Interest Income Expense | 2.98 | 14.37 | 15.34 | 11.36 |
| Interest Expense Non Operating | 0.08 | 0.01 | 0.03 | 0 |
| Interest Income Non Operating | 3.06 | 14.37 | 15.34 | 11.36 |
| Operating Revenue | 203.56 | 245.11 | 312.97 | 376.57 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Twist Bioscience Corporationthis co. | TWST | $3.5B | - | 7.62 | -16.4% | -30.08 |
| Travere Therapeutics, Inc. | TVTX | $3.7B | - | 31.75 | -22.2% | -1780.31 |
| Oruka Therapeutics, Inc. | ORKA | $3.4B | - | 7.07 | -22.5% | -24.94 |
| Liquidia Corporation | LQDA | $3.4B | - | 74.37 | -154.0% | -66.91 |
| Brookdale Senior Living Inc. | BKD |
| $3.4B |
| - |
| -74.95 |
| 605.6% |
| 18.66 |
| Edgewise Therapeutics, Inc. | EWTX | $3.3B | - | 6.20 | -32.1% | -14.47 |
| LivaNova PLC | LIVN | $3.2B | - | 2.68 | -20.2% | 11.72 |
| Tango Therapeutics, Inc. | TNGX | $3.2B | - | 8.66 | -29.3% | -26.04 |
| Beam Therapeutics Inc. | BEAM | $3.0B | - | 2.35 | -6.5% | -5.05 |
| Peer Median | - | - | 6.63 | -22.4% | -19.71 | |